A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 190-198

  Smith, Neil R ^a   Womack, Christopher ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

assay validation; immunohistochemistry; oncology drug development

Indexed keywords

MYC PROTEIN; PROTEIN MYB; TUMOR MARKER;

ANTIBODY SPECIFICITY; CANCER TISSUE; HUMAN; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; ONCOGENE C MYB; ONCOGENE C MYC; ONCOLOGY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; UPREGULATION; VALIDATION STUDY; WESTERN BLOTTING;

ASSAY VALIDATION; IMMUNOHISTOCHEMISTRY; ONCOLOGY DRUG DEVELOPMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; IMMUNOHISTOCHEMISTRY; MEDICAL ONCOLOGY; NEOPLASMS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WORKFLOW;

EID: 84890284498     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4262     Document Type: Review

References (13)

1. Sarker D, Workman P,. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007; 96: 213-268.
2. Tan DS, Thomas GV, Garrett MD, et al., Biomarker-driven early clinical trials in oncology a paradigm shift in drug development. Cancer J 2009; 15: 406-420.
3. Hodgson DR, Whittaker RD, Herath A, et al., Biomarkers in oncology drug development. Mol Oncol 2009; 3: 24-32.
4. Drucker E, Krapfenbauer K,. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J 2013; 4: 7.
5. Duffy MJ, Crown J,. Companion biomarkers: paving the pathway to personalized treatment for cancer. Clin Chem 2013; 59: 1447-1456.
6. Vincent MD, Kuruvilla MS, Leighl NB, et al., Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol 2012; 19: S33-44.
7. Smith NR, Baker D, James NH, et al., Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010; 16: 3548-3561.
8. Dunstan RW, Wharton KA, Jr., Quigley C, et al., The use of immunohistochemistry for biomarker assessment-can it compete with other technologies? Toxicol Pathol 2011; 39: 988-1002.
9. Cummings J, Ward TH, greystoke A, et al. Biomarker method validation in anticancer drug development. Br J Pharmacol 2008; 153: 646-656.
10. Bordeaux J, Welsh A, Agarwal S, et al., Antibody validation. Biotechniques 2010; 48: 197-209.
11. Mandell JW,. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 2003; 163 (5): 1687-1698.
12. Findlay JW, Smith WC, Lee JW, et al., Validation of immunoassays for bioanalysis a pharmaceutical industry perspective. J Pharm Biomed Anal 2000; 21: 1249-1273.
13. US Department of Health and Human Sciences, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry. Bioanalytical Method Validation, 2001.